

# GAVI'S VACCINE INVESTMENT STRATEGY (VIS)

---

BOARD TECHNICAL BRIEFING  
13 June 2017, Geneva



Reach every child

[www.gavi.org](http://www.gavi.org)

# Agenda

---

1. Overview of the VIS and Gavi's portfolio (**15 mins**) – Gavi Secretariat
2. Landscaping of candidate investments (**10 mins**) – Martin Friede, WHO
3. Rabies case study (**10 mins**) – Bernadette Abela-Ridder, WHO
4. Strategic considerations for 2018 VIS (**5 mins**) – Gavi Secretariat
5. Moderated discussion (**45 mins**)


# 1

## Overview of VIS and Gavi's portfolio

---

# VIS one component of Gavi's country support

---



# VIS is Gavi's approach to identifying future vaccine investment priorities

## Objectives:


- To identify future immunisation investments of high public health importance to Gavi-supported countries for inclusion in Gavi's portfolio in the next 5 years
- *To develop guidance on future investment priorities beyond 5 years*

## Outputs:


1. Board-approved investment for specific immunisation product(s), identified through an evidence-based process
2. *Guidance (non-binding) for longer-term (i.e., beyond 5 years) investment priorities*



# A robust and evidence-based process will be conducted over the next 18 months




# Objectives of investments more diverse over time




# However, the majority of Gavi spend is still focused on uptake of high impact vaccines

---






# Vaccine investments increasingly targeted at specific sets of countries




\*Universal: all Gavi countries; Targeted: focused on sub-set of GAVI countries; Other: outbreak response, learning agenda

# Initially focused primarily on infant/EPI, vaccine investments now span a number of age groups



# Infant/EPI schedule represents a decreasing proportion of Gavi's spend

---



# 2

## Scoping the vaccine landscape for potential candidates

---

# 3

## Rabies case study

# 4

## Strategic considerations for VIS 2018

---

# VIS has traditionally prioritised health impact, but opportunity to broaden investment lens

---

## Previous VIS

Overall and U5 mortality

Procurement cost per deaths averted

## Current VIS

**Additional lenses for health impact?**  
Morbidity, AMR, strengthening delivery platforms

**Looking beyond direct health impact?**  
“Global public good” vaccines (e.g., epidemics; eradication)


# Potential additional health impact lens: *Strengthening “delivery platforms”*

---





# Potential additional health impact lens: *Reduction in antimicrobial resistance (AMR)*



## Pneumococcal conjugate vaccine example


In South Africa, rates of **IPD characterised by drug-resistant isolates declined by >80% in <2yo**

Universal global coverage could **potentially reduce antibiotic use by 11.4m days annually in <5yo**

# Looking beyond direct health impact: *Vaccines for epidemic preparedness*


## Global deaths

*Relative trends, not same scale*



- Differentiating factor: sporadic and uncertain nature of disease
- Vaccines as preparedness and risk mitigation tool
- Vaccines potentially never utilised

# Potentially taking a longer-term view within the VIS



## Potential differentiated approach within the VIS

### Multiple investment objectives

- New / additional “direct health impact” vaccines
- “Global public good” vaccines
- Strengthening / expanding current programmes

### Different decision outcomes / modalities

- New vaccine country support window
- Global stockpile
- Learning agenda
- Signalling future priorities (vaccines in 5-10 year window)

*May require distinct decision frameworks and evaluation criteria*

## Questions for discussion

---

1. To what extent should Gavi consider other dimensions of vaccine impact (e.g., morbidity, AMR, economic impact)?
2. What is Gavi's comparative advantage in strengthening delivery platforms (e.g., maternal vaccination)?
3. Should Gavi also signal interest in longer-term (>5 year) vaccine priorities and how could this be effectively done?
4. What is Gavi's role in supporting "global public goods" versus direct health impact in Gavi countries?

# BACKUP

---

# Proportion of disbursements by scope of investment

---

